Kronos Bio Announces Participation in Upcoming Investor Conferences
November 22 2022 - 4:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that members of the management team will participate in fireside
chats at the following investor conferences:
- Piper Sandler’s 34th
Annual Healthcare Conference on Tuesday, November 29, 2022, at
11:30 a.m. ET; and
- Evercore ISI’s 5th
Annual HealthCONx on Thursday, December 1, 2022, at 1 p.m. ET.
The fireside chats will be available on
the Investors & Media section of the company’s website
at www.kronosbio.com. A replay of the webcasts will be
archived and available for one month following each event.
About Kronos Bio, Inc.Kronos
Bio is a biopharmaceutical company that is advancing two
investigational compounds in clinical trials for patients with
cancer. The company is developing the CDK9 inhibitor, KB-0742, as a
treatment for MYC-amplified solid tumors, and lanraplenib, a
next-generation SYK inhibitor, for patients with
relapsed/refractory FLT3-mutated acute myeloid leukemia. The
company’s scientific focus is on developing medicines that target
the dysregulated transcription that is the hallmark of cancer and
other serious diseases.
Kronos Bio is based in San Mateo, Calif., and
has a research facility in Cambridge, Mass. For more information,
visit www.kronosbio.com or follow the company on LinkedIn.
Company contact:Marni KottleKronos
Bio650-900-3450mkottle@kronosbio.com
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Media:Sheryl SeapyReal
Chemistry949-903-4750sseapy@realchemistry.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jul 2023 to Jul 2024